Journal: Advanced Science
Article Title: CD3ɛ Nanobody‐Engineered Extracellular Vesicles Driving In Vivo Generation of TCE‐secreting CAR‐Ts for Solid Tumor Therapy With Memory Response and Minimal Immunogenicity
doi: 10.1002/advs.202519440
Figure Lengend Snippet: CD3ε‐Nb EVs showed higher transfection efficiency with minimal immunogenicity risk than lipid and viral‐carrier‐based approaches. (A) Schematic protocol for evaluating the immunological responses of CD3ε‐Nb mEVs, liposomes, LNPs, and LVs in an immunocompetent mouse model. C57BL/6 mice ( n = 5) were treated with or without 2 × 10 9 particles of CD3ε Nb‐conjugated liposomes, LNPs, NIH/3T3‐derived CD3ε Nb‐mouse CD63‐expressing EVs (CD3ε‐Nb mEVs), or CD3ε‐Nb LVs weekly for four weeks through tail vein injection. All mice were sacrificed, and their serum and splenocytes were collected. (B) The serum contents of C1q, ALT, IFN‐α, IL‐6, IFN‐γ, and IL‐1β were detected using ELISA kits according to the user instructions. (C) The presence of IgM and IgG against CD3ε Nb‐expressing liposomes, LNPs, LVs, or mEVs in the serum was determined by an ELISA‐based assay through coating with CD3ε‐Nb liposomes, LNPs, LVs, or mEVs. (D) The Nb‐CAR‐expressing splenocytes were determined by flow cytometry using specific antibodies against VHH and mouse CD3. (E–J) Minimal influence on EV‐mediated in viv o Nb‐CAR.TCE‐T generation by prior exposure of lipid‐based carriers. (E) The expression of HLA‐G on HLA‐G‐overexpressing GL261‐luc cells was measured by flow cytometry. (F) Representative protocol for investigating the effect of prior exposure with liposomes and LNPs on subsequent transgene delivery using CD3ε‐Nb mEVs in a tumor‐bearing syngeneic mouse model. C57BL/6 mice ( n = 3 and 5) were orthotopically implanted with GL261 cells (2 × 10 5 cells) and subsequently treated with 2 × 10 9 particles of CD3ε Nb‐conjugated liposomes, LNPs, NIH/3T3‐derived CD3ε Nb‐mouse CD63‐expressing EVs (CD3ε‐Nb mEVs), or CD3ε‐Nb LVs weekly for two weeks through tail vein injection. The mice were then infused with CD3ε‐Nb liposomes, LNPs, or mEVs loaded with the Nb‐CAR.TCE transgene (1 mg/kg) in the following two weeks. (G) All mice were sacrificed on day 21 after the first infusion, and the expression of Nb‐CAR on splenocytes was measured by flow cytometry using VHH and mouse CD3‐specific antibodies (G). Or (H–J) the tumor growth was monitored weekly using the IVIS system to detect the bioluminescent signals (H,I), and the survival rates of these mice were documented (J). The in vivo tumor growth data were presented as mean ± SEM and analyzed using one‐way ANOVA to compare means across multiple groups. The survival rate was analyzed using the Kaplan–Meier method and log‐rank test. Statistical significance was set at p ‐value < 0.05. * p < 0.05, ** p < 0.01, *** p < 0.001. The results of the experiments were analyzed using one‐way ANOVA to compare means across multiple groups. Data are mean ± SD, * p < 0.05; ** p < 0.01; *** p < 0.001.
Article Snippet: The levels of human IL‐6 (#HS600C), mouse IL‐6 (#M6000B), human IFN‐γ (#DIF50C), mouse C1q (#MCD930), mouse IL‐6, (#MFNAS0), mouse IFN‐α (#MIF00), mouse IFN‐γ (#MIF00), human TNF‐α (#DTA00D), mouse TNF‐α (#MTA00B), human IL‐1β (#HSLB00D), and mouse IL‐1β (#MHSLB00) were measured, along with the multiplex cytokine array set (which includes human CCL3/MIP‐1α, CCL4/MIP‐1β, CD25/IL‐2Rα, GM‐CSF, IFN‐γ, IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12/IL‐23 p40, IL‐17/IL‐17A, and TNF‐α), in the serum samples and coculture supernatants using ELISA kits (R&D Systems) and ABplex Human Cytokine 15‐Plex Assay Kit (RK05202, Abclonal), following the manufacturer's instructions.
Techniques: Transfection, Immunopeptidomics, Liposomes, Derivative Assay, Expressing, Injection, Enzyme-linked Immunosorbent Assay, Flow Cytometry, In Vivo